Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423634 | 0.91 | PTGS2 (0.57) | AKR1C3AKR1C2PTGS2PTGS1LMNA | |
| SCHEMBL5560102 | 0.90 | PTGS2 (0.55) | AKR1C3AKR1C2PTGS2PTGS1LMNA | |
| SCHEMBL5553724 | 0.89 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1LMNA | |
| SCHEMBL6467082 | 0.89 | PTGS2 (0.62) | AKR1C3AKR1C2PTGS2PTGS1TRPV1 | |
| SCHEMBL6424062 | 0.89 | PTGS2 (0.64) | AKR1C3AKR1C2PTGS2PTGS1TRPV1 | |
| SCHEMBL5554455 | 0.89 | PTGS2 (0.58) | AKR1C3AKR1C2PTGS2PTGS1TRPV1 | |
| SCHEMBL6426630 | 0.88 | AKR1C3 (0.55) | AKR1C3AKR1C2PTGS2PTGS1LMNA | |
| SCHEMBL6461554 | 0.88 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS2PTGS1LMNA | |
| SCHEMBL6461262 | 0.87 | PTGS2 (0.60) | AKR1C3AKR1C2PTGS2PTGS1LMNA | |
| SCHEMBL5800745 | 0.87 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS2PTGS1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006050120-A2 | SYNTHESIS OF COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | AKR1C3 585/4885AKR1C2 342/4885PTGS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.